[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612159":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":25,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":30,"collaborators":11,"id":34,"slug":11,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":11,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":48,"conditions":49,"keywords":11,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":11},{"fullName":5,"class":6},"Chongqing University Cancer Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"1.\"Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0\" 2.\"Therapeutic Effect as Assessed by RECIST1.1\"",null,"4 years",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NA","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":11,"interventionNames":23},"Radical radiotherapy for IIb cervical cancer to reduce the irradiation area","EXPERIMENTAL",[24],"Radiation: The external irradiation area only covers the entire uterus (including the primary lesion in the cervix), bilateral parametrium, and 3 cm below the cervical\u002Fvaginal lesions.",[26],{"type":27,"name":28,"description":28,"armGroupLabels":29,"otherNames":11},"RADIATION","The external irradiation area only covers the entire uterus (including the primary lesion in the cervix), bilateral parametrium, and 3 cm below the cervical\u002Fvaginal lesions.",[21],{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Dongling Zou","Director of Dept. of Gynecological Oncology Chongqing University Cancer Hospital","100612159",false,"NCT07249957","Reducing Radiation Target Volume for Stage IIb Cervical Cancer","Reducing Radiation Target Volume in Radical Radiotherapy for Stage IIb Cervical Cancer: A Single-arm Exploratory Study","Inclusion Criteria:\n\n1. The patient voluntarily participated in this study and signed the informed consent form;\n2. Age range: 50 to 75 years old;\n3. Patients with cervical cancer who had not undergone surgery or chemotherapy and were initially diagnosed with squamous cell carcinoma by pathological histology, and were HPV high-risk positive;\n4. According to the 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system, it was stage IIb (tumor size \\\u003C 4 cm);\n5. ECOG score: 0 to 1, with an expected survival of more than 6 months;\n6. Pregnant women must undergo a pregnancy test (serum or urine) 7 days before enrollment, and the result must be negative, and they are willing to use appropriate contraceptive methods during the trial;\n7. According to the investigator's judgment, there are no absolute contraindications to radiotherapy and chemotherapy or surgery, and they can comply with the trial protocol.\n\nExclusion Criteria:\n\n1. Active or uncontrolled severe infections;\n2. Cirrhosis, decompensated liver disease;\n3. History of immunodeficiency, including HIV positive or having other acquired congenital immune deficiency diseases;\n4. Chronic renal insufficiency and renal failure;\n5. Patients with other malignancies that require treatment and\u002For newly diagnosed within 5 years;\n6. Myocardial infarction, severe arrhythmia, and ≥ grade 2 congestive heart failure (NYHA classification);\n7. Patients who have undergone pelvic artery embolization;\n8. Patients who have received radiotherapy for pelvic malignant tumors in the past;\n9. Patients who have received partial hysterectomy or radical hysterectomy in the past;\n10. Patients with a history of severe allergic reaction to platinum-based chemotherapy drugs;\n11. Comorbidities, requiring the use of drugs that cause significant liver and kidney damage during treatment, such as tuberculosis, etc.;\n12. Patients who cannot understand the experimental content and cannot cooperate, or who refuse to sign the informed consent form;\n13. Patients with serious accompanying diseases or other special conditions that seriously endanger their safety or affect their ability to complete the study.","FEMALE","50 Years","75 Years",{"count":44,"type":45},60,"ESTIMATED","INTERVENTIONAL",[14],"This is a domestic single-center prospective clinical trial. The study selected patients with histologically confirmed cervical squamous cell carcinoma, diagnosed as stage IIb according to the FIGO 2018 staging principle (tumor size \\\u003C 4 cm). The patients first received 6 cycles of induction chemotherapy (carboplatin (AUC2) + paclitaxel (80 mg\u002Fm2), q1w), followed by concurrent chemoradiotherapy with a platinum-based regimen. The external beam radiation field only covered the entire uterus (including the primary lesion of the cervix), the bilateral parametrium, and the lesion of the cervix\u002Fvagina extending 3 cm downward. A total of 60 participants are planned to be included in the study.",[50],"Stage IIb Cervical Cancer Radical Radiotherapy","NOT_YET_RECRUITING","2025-11-18",{"date":54,"type":55},"2025-11-25","ACTUAL",{"date":57,"type":45},"2025-11",{"date":59,"type":45},"2029-10",{"name":5,"class":6}]